Table 1: Patient Characteristics.

VariableRPP ( )RRP ( )RALP ( )P-value

AgeAvg. (SD)61.1(7.6)61.7(6.8)60.1(7.3)0.12
Pre-op PSA (ng/mL)Avg. (SD)5.64(2.69)8.89(9.44)6.67(7.28)0.001
Gleason score
6No. (%)26(28.3)38(21.1)91(47.6)<0.001
 745(48.9)82(45.6)89(46.6)0.87
 8–1021(22.8)60(33.3)11(5.5) 0.001
Tumor volume (%)Avg. (SD)17.7(14.4)18.0(15.8)14.8(11.8)0.056
10No. (%)40(43.5)80(44.4)103(53.9)0.11
 10.1 to 2024(26.1)44(24.4)62(32.5)0.21
 20.1 to 3014(15.2)29(16.1)27(14.1)0.87
3014(15.2)27(15)15(7.9)0.064
Risk classification
 LowNo. (%)24(26.1)37(20.6)85(44.5) 0.001
 Intermediate47(44.6)83(46.1)93(48.7)0.73
 High21(22.8)59(32.8)13(6.8) 0.001
Pathological stage
T2No. (%)71(77.2)131(72.8)172(90) 0.001
 pT2a18(19.6)19(10.6)27(0.14)0.12
 pT2b2(2.2)3(1.7)5(2.6)0.82
 pT2c51(55.4)109(60.6)140(73.3)0.004
pT3a21(22.8)49(27.2)19(9.9)<0.001
EBL Avg.475999.1189.2<0.001
Length of stay (days)Avg.1.292.281.23<0.001